Roden Richard B相关文献与解析，生知库 | 链接生命科学的每一步

Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.

在小鼠中，将合成的 TLR4 激动剂与 RG1-VLP 疫苗结合使用，可以实现免疫谱多样性

doi:10.1016/j.vaccine.2024.126577

Matthews Rebecca L, Khan Nazneen, Beckman Bradley, Sharma Simran, Dietz Zackary, Picking William D, Izmirlian Grant, Sanders Chelsea, Stocks Stacy M, Difilippantonio Simone, Kirnbauer Reinhard, Roden Richard B, Pinto Ligia A, Shoemaker Robert H, Ernst Robert K, Marshall Jason D

其它

发表日期：2025

文献求助收藏

Optimizing Recruitment and Retention in Cancer Clinical Trials in Low-Resource Settings: Barriers and Facilitators From Nigerian Provider's Perspectives

在资源匮乏的环境下优化癌症临床试验的招募和保留：来自尼日利亚医疗服务提供者的视角——障碍与促进因素

期刊:JCO Global Oncology

影响因子:3

doi:10.1200/GO-24-00308

Olakunde, Babayemi O; Idemili-Aronu, Ngozi; Friebel-Klingner, Tara M; Chike-Okoli, Adaeze; Itanyi, Ijeoma U; Onyeka, Tonia C; Levinson, Kimberly; Rositch, Anne F; Roden, Richard B S; Wu, Tzyy-Choou; Ezeanolue, Echezona E

Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria

参与癌症临床试验的障碍和促进因素：尼日利亚ICON-3实践研究网络中患者的视角

期刊:JCO Global Oncology

影响因子:3

doi:10.1200/GO-25-00181

Idemili-Aronu, Ngozi; Olakunde, Babayemi O; Friebel-Klingner, Tara M; Chike-Okoli, Adaeze; Itanyi, Ijeoma U; Onyeka, Tonia C; Rositch, Anne F; Roden, Richard B S; Wu, Tzyy-Choou; Ezeanolue, Echezona E; Levinson, Kimberly

Clinicopathologic Features and Viral Status of Low-risk HPV6 and HPV11-Associated Squamous Cell Carcinoma of the Uterine Cervix and Vulva

子宫颈和外阴低危型HPV6和HPV11相关鳞状细胞癌的临床病理特征和病毒状态

期刊:American Journal of Surgical Pathology

影响因子:

doi:10.1097/PAS.0000000000002367

Williams, Guy A 2nd; Wu, Annie A; Eugene, Henrietta C; Tsai, Ya-Chea; Wong, Margaret; Nonogaki, Hiro; Roden, Richard B S; Hung, Chien-Fu; Wu, Tzyy-Choou; Vang, Russell; Xing, Deyin

A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer

一项关于HPV16 L2E7E6融合蛋白疫苗接种部位治疗后HPV16阳性宫颈癌的随机试点研究

期刊:Gynecologic Oncology

影响因子:

doi:10.1016/j.ygyno.2025.08.006

Gaillard, Stéphanie; Alvarez, Jade; Zhang, Tianbei; Wang, Hao; Tsai, Hua-Ling; Cope, Leslie; Deery, Amy; Palande, Vikrant; Lee, Chi-Fen; Fader, Amanda N; Huh, Warner K; Arend, Rebecca C; Liang, Margaret I; Straughn, J Michael Jr; Vang, Russell; Ostrander, Darin; Horner, Karen; Zhang, Li; Singh, Dipika; Smith, Kellie N; Wu, T C; Leath, Charles A 3rd; Roden, Richard B S

Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis

复发性呼吸道乳头状瘤病中 VEGF 受体和免疫检查点的分析

期刊:Laryngoscope

影响因子:

doi:10.1002/lary.31253

Lam, Brandon; Miller, Jonas; Kung, Yu Jui; Wu, T C; Hung, Chien-Fu; Roden, Richard B S; Best, Simon R

Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1

肌注 pNGVL4a-Sig/E7(detox)/HSP70 DNA 和 TA-CIN 蛋白疫苗治疗 HPV16+ ASC-US、ASC-H 或 LSIL/CIN1 的安全性研究

期刊:Cancer Prevention Research

影响因子:2.6

doi:10.1158/1940-6207.CAPR-22-0413

Einstein, Mark H; Roden, Richard B S; Ferrall, Louise; Akin, Mark; Blomer, Allison; Wu, T C; Chang, Yung-Nien

Cervical Cancer Immunotherapy: Facts and Hopes

宫颈癌免疫疗法：事实与希望

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-20-2833

Ferrall, Louise; Lin, Ken Y; Roden, Richard B S; Hung, Chien-Fu; Wu, T-C

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.

开发针对人乳头瘤病毒 16 (HPV16) 和 HPV18 的 E6 和 E7 蛋白的 DNA 疫苗，用于免疫治疗，并结合重组痘苗病毒加强和 PD-1 抗体

期刊:mBio

影响因子:4.7

doi:10.1128/mBio.03224-20

Peng Shiwen, Ferrall Louise, Gaillard Stephanie, Wang Chenguang, Chi Wei-Yu, Huang Chuan-Hsiang, Roden Richard B S, Wu T-C, Chang Yung-Nien, Hung Chien-Fu

Nano-Luciferase complementation assay of human herpesvirus 8 chemo/cytokine-receptor interactions

人疱疹病毒8型化疗/细胞因子受体相互作用的纳米荧光素酶互补分析

Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.

在小鼠中，将合成的 TLR4 激动剂与 RG1-VLP 疫苗结合使用，可以实现免疫谱多样性

Optimizing Recruitment and Retention in Cancer Clinical Trials in Low-Resource Settings: Barriers and Facilitators From Nigerian Provider's Perspectives

在资源匮乏的环境下优化癌症临床试验的招募和保留：来自尼日利亚医疗服务提供者的视角——障碍与促进因素

Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria

参与癌症临床试验的障碍和促进因素：尼日利亚ICON-3实践研究网络中患者的视角

Clinicopathologic Features and Viral Status of Low-risk HPV6 and HPV11-Associated Squamous Cell Carcinoma of the Uterine Cervix and Vulva

子宫颈和外阴低危型HPV6和HPV11相关鳞状细胞癌的临床病理特征和病毒状态

A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer

一项关于HPV16 L2E7E6融合蛋白疫苗接种部位治疗后HPV16阳性宫颈癌的随机试点研究

Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis

复发性呼吸道乳头状瘤病中 VEGF 受体和免疫检查点的分析

Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1

肌注 pNGVL4a-Sig/E7(detox)/HSP70 DNA 和 TA-CIN 蛋白疫苗治疗 HPV16+ ASC-US、ASC-H 或 LSIL/CIN1 的安全性研究

Cervical Cancer Immunotherapy: Facts and Hopes

宫颈癌免疫疗法：事实与希望

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.

开发针对人乳头瘤病毒 16 (HPV16) 和 HPV18 的 E6 和 E7 蛋白的 DNA 疫苗，用于免疫治疗，并结合重组痘苗病毒加强和 PD-1 抗体